Monoclonal anticardiolipin antibodies derived from SLE-prone mice demonstrate a polyspecific nature, reacting with various phospholipids, cells, and molecules.
Answers are grounded in this paper and cite their sources.
Monoclonal aCL polyspecificity in SLE-prone mice does not inform human APS care; leaves open whether cross-reactivity drives clinical manifestations.
The objective of this study was to clarify the specificity of anticardiolipin antibodies (aCL). Eighteen monoclonal hybridoma aCL from systemic lupus erythematosus (SLE)-prone MRL/Mp-lpr/lpr mice were established, and the reactivity of monoclonal aCL to phospholipids, DNA, nuclei of human epithelial cells, platelets, vascular endothelial cells, heparin, protein C and thrombomodulin was examined. All the 18 monoclonal aCL reacted with phosphatidylserine and some showed reactivity to phosphatidylinositol and phosphatidylcholine. Six of 16 monoclonal aCL were demonstrated to have the property of lupus anticoagulant. Monoclonal aCL were classified into three categories, in terms of DNA-binding specificity. Ten of 18 aCL had characteristics of antinuclear antibodies. Six of 11 aCL reacted with platelets. Three of 18 aCL were bound to vascular endothelial cells and to heparin. No monoclonal aCL reacted with protein C or thrombomodulin. Therefore, the conclusion was made that monoclonal aCL from SLE mice showed a polyspecific nature.
No takes yet. Share an insight, caveat, or question.
Ichikawa et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: